JPRN-UMIN000033712
Completed
未知
Exploratory study of prediction marker for efficacy and safety of TBI-1301 - Exploratory study of TBI-1301
Immuno-Gene Therapy, Mie University Graduate School of Medicine0 sites9 target enrollmentSeptember 10, 2018
ConditionsRefractory solid tumor
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Refractory solid tumor
- Sponsor
- Immuno-Gene Therapy, Mie University Graduate School of Medicine
- Enrollment
- 9
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Not having enrolled to TBI\-1301 clinical trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation and utilization of predictive factors to prevent outbreaks caused by methicillin-resistant Staphylococcus aureus in neonatal intensive care units -Focusing on Environmental Factors (Secondary Research)JPRN-UMIN000050682niversity of Human Enviroments40
Recruiting
Not Applicable
Prospective study on identification of effectiveness, safety and effect predictors of benralizumab for bronchial asthmaJPRN-UMIN000031951Japanese Red Cross Medical Center25
Completed
Not Applicable
A study of evaluation to the predictive biomarker of Nivolumab in peripheral blood and pleural effusion.previously treated patients with advanced non-small-cell lung cancerJPRN-UMIN000023873Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine10
Not yet recruiting
Not Applicable
Development of prediction model for the efficacy of anti-PD-1 antibody on malignant pleural mesotheliomaJPRN-UMIN000034089Hyogo college of medicine50
Active, not recruiting
Phase 1
Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen Markern auf die Wirksamkeit und Nebenwirkungsrate bei postmenopausalen, steroidhormonrezeptorpositiven Mammakarzinomspatientinnen, die mit Letrozol behandelt werden. - PreFaceEUCTR2008-004874-42-DEInstitut für Frauengesundheit GmbH3,500